Kola Olivia, Shukla Pratik, Haque Humza, Kumar Abhishek
Rutgers - New Jersey Medical School, Newark, NJ, USA.
Department of Radiology, Rutgers - New Jersey Medical School, Newark, NJ, USA.
Cardiovasc Intervent Radiol. 2025 Apr;48(4):559-566. doi: 10.1007/s00270-025-04012-y. Epub 2025 Mar 19.
To assess the safety and efficacy of Obsidio™ conformable embolic (CE) for embolization in the peripheral vasculature.
A retrospective review of the first 21 patients treated with CE was performed. Eighteen (85.7%) patients were male, and median age was 61.5 years (range, 12-89 years). Technical success was defined as stasis as assessed by a static contrast column for at least 5 heartbeats on post-embolization angiography. For procedures of peripheral vascular hemorrhage, clinical success was defined as hemorrhage resolution without reintervention within 30-day follow-up.
Indications for embolization were peripheral arterial hemorrhage (n = 13), preoperative tumor embolization (n = 4), preoperative embolization of renal cell carcinoma prior to cryoablation (n = 2), redistribution of flow prior to Yttrium-90 radioembolization to prevent nontarget radiation delivery (n = 1), and parastomal variceal embolization (n = 1). Embolization was performed via 2.4 or 2.8 French microcatheters flushed with saline prior to embolization. Most procedures (20/21) utilized < 1 cc of embolic, with the quantity used ranging between 0.1 and 1.4 cc. The amount of embolic injected was determined by the embolization endpoint, i.e., filling of the vessel intended for embolization. CE was used in combination with coils placed prior to CE in 4 procedures. Follow-up was a median of 57 days (range 0-244 days). Complete stasis was achieved in 100% (n = 21/21) of procedures. There were no post-procedure adverse events or rebleeding.
CE resulted in reliable vessel occlusion with no cases of rebleeding or reintervention and with no procedure-related adverse events in this series.
Level 4, Case Series.
评估Obsidio™顺应性栓塞剂(CE)在外周血管系统栓塞中的安全性和有效性。
对首批21例接受CE治疗的患者进行回顾性研究。18例(85.7%)为男性,中位年龄61.5岁(范围12 - 89岁)。技术成功定义为栓塞后血管造影显示静态造影剂柱停滞至少5个心动周期。对于外周血管出血的手术,临床成功定义为在30天随访内出血消退且无需再次干预。
栓塞的适应证包括外周动脉出血(n = 13)、术前肿瘤栓塞(n = 4)、冷冻消融术前肾细胞癌的术前栓塞(n = 2)、钇-90放射性栓塞前血流重新分布以防止非靶区辐射(n = 1)以及造口旁静脉曲张栓塞(n = 1)。栓塞前通过用生理盐水冲洗的2.4或2.8法国微导管进行栓塞。大多数手术(20/21)使用的栓塞剂<1 cc,使用量在0.1至1.4 cc之间。注入的栓塞剂数量由栓塞终点决定,即预期栓塞血管的充盈情况。4例手术中CE与在CE之前放置的弹簧圈联合使用。随访中位时间为57天(范围0 - 244天)。100%(n = 21/21)的手术实现了完全停滞。术后无不良事件或再出血。
在本系列中,CE导致可靠的血管闭塞,无再出血或再次干预病例,且无手术相关不良事件。
4级,病例系列。